REMICADE® may provide lasting control of the symptoms and flares of Crohn's disease (CD), with as few as 6 treatments a year. That's 1 treatment every 8 weeks after the first 3 starter doses. While individual results may vary, many people with moderately to severely active CD who haven't responded well to other therapies have found that REMICADE®:
REMICADE® is one of a class of medications called biologics, which take a different approach to helping control the symptoms of CD.
*Only your doctor can decide if reducing or stopping steroid use is appropriate for you. Individual results may vary.
REMICADE® can lower your ability to fight infections. Serious and sometimes fatal events can occur. There have been reports of serious infections including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that have spread throughout the body. Lymphoma, including a fatal kind called hepatosplenic T-cell lymphoma, and other cancers have been reported in children and adults taking REMICADE®. Some people with heart failure should not take REMICADE®. Other serious side effects reported include skin cancer, hepatitis B, liver injury, blood problems, allergic reactions, nervous system problems, or lupus-like syndrome. To learn more about these and other risks, please read the Important Safety Information [1] and the Medication Guide
[2], and talk with your doctor.
Download the Medication Guide
[2] to learn more about REMICADE®. (Requires Adobe® Reader®. Click here [3] to download.)
Only your doctor can recommend a course of treatment after checking your health condition. REMICADE® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE®.
Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. Hepatosplenic T-cell lymphoma, a rare form of fatal lymphoma, has occurred mostly in teenage or young adult males with Crohn’s disease or ulcerative colitis who were taking REMICADE® and azathioprine or 6-mercaptopurine. For children and adults taking TNF blockers, including REMICADE®, the chances of getting lymphoma or other cancers may increase.
You should discuss any concerns about your health and medical care with your doctor.
What should I tell my doctor before I take REMICADE®?
You should let your doctor know if you have or ever had any of the following:
Also tell your doctor if you:
What should I watch for and talk to my doctor about before or while taking REMICADE®?
The following serious (sometimes fatal) side effects have been reported in people taking REMICADE®.
You should tell your doctor right away if you have any of the signs listed below:
For more information, please download the Full Prescribing Information and Medication Guide and discuss it with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Links:
[1] http://www.remicade.com/crohns-disease/about-remicade#isi
[2] http://www.remicade.com/shared/product/remicade/medication-guide.pdf
[3] http://get.adobe.com/reader
[4] http://www.remicade.com/crohns-disease/how-remicade-works